Regulus Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen collectively reported a 0.3% beneficial ownership stake in Regulus Therapeutics Inc., primarily through warrants.
Deep Track Capital and its affiliates have fully divested their beneficial ownership in Regulus Therapeutics Inc., reporting 0% stake.
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have filed an amended Schedule 13G, disclosing a 3.9% passive beneficial ownership in Regulus Therapeutics Inc.
Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a passive 5.9% beneficial ownership stake in Regulus Therapeutics Inc., including shares issuable from warrants.